Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma
Syeda Saba Kareem,Neena Viswanathan,Solmaz Sahebjam,Nam D Tran,Tyra Gatewood,Katherine Tobon,Rachid Baz,Yolanda Piña,Kenneth H Shain,Sepideh Mokhtari
DOI: https://doi.org/10.2147/OTT.S365657
IF: 4
2022-09-06
OncoTargets and Therapy
Abstract:Syeda Saba Kareem, 1 Neena Viswanathan, 2 Solmaz Sahebjam, 2 Nam D Tran, 2 Tyra Gatewood, 2 Katherine Tobon, 1 Rachid Baz, 1 Yolanda Piña, 2 Kenneth H Shain, 1, 3 Sepideh Mokhtari 2 1 Malignant Hematology Department, Moffitt Cancer Center, Tampa, FL, USA; 2 Neuro-Oncology Department, Moffitt Cancer Center, Tampa, FL, USA; 3 Tumor Biology Department, Moffitt Cancer Center, Tampa, FL, USA Correspondence: Syeda Saba Kareem, Malignant Hematology Department, Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL, 33612, Tel +850-321-4383, Fax +813-449-8246, Email Leukoencephalopathy in the setting of multiple myeloma (MM) is a rare demyelinating condition, with few reported cases in literature. Daratumumab is a CD38 targeted monoclonal antibody that has been widely used for the management of MM. In the absence of central nervous system (CNS) disease, many medication-induced leukoencephalopathy cases reported with MM, including daratumumab-induced, are associated with progressive multifocal leukoencephalopathy (PML) and John Cunningham (JC) virus. Currently, there are no reported cases of daratumumab-induced leukoencephalopathy among patients without CNS involvement or PML. We discuss 2 patients who developed leukoencephalopathy while receiving daratumumab-based therapy without evidence of PML or CNS disease. Both patients had baseline MRIs without significant white matter changes before daratumumab-based therapy. Patients began experiencing neurological deficits about 6 to 8 months after daratumumab-based therapy initiation. One patient passed away before being assessed for improvement of symptoms with daratumumab cessation. The second patient had some stabilization of symptoms after cessation; however, the leukoencephalopathy remained irreversible. As the class of anti-CD38 monoclonal antibodies expands in MM therapy, we highlight a potential treatment complication and the importance of detecting leukoencephalopathy early among patients receiving anti-CD38 therapy. We recommend vigilant monitoring of any new or worsening neurological symptoms to avoid serious complications of irreversible leukoencephalopathy. Keywords: anti-CD38, monoclonal antibody, neurotoxicity, plasma cell disorder, white matter changes, daratumumab, leukoencephalopathy, case report Leukoencephalopathy is a clinical condition associated with functional decline in neuronal capabilities secondary to structural alterations in cerebral white matter, which are induced by changes to the myelin. There are many different types of leukoencephalopathy, which can result from genetic mutations; can be acquired via vascular injury, infections, inflammatory processes, nutritional deficiencies, traumatic events, or neoplastic disease; or can be caused by toxicity/adverse effects from medications. 1,2 In the setting of multiple myeloma (MM), leukoencephalopathy is rare and has been predominantly documented secondary to central nervous system (CNS) disease, paraneoplastic syndrome, infectious processes, genetic conditions, and medication use. 3–6 Leukoencephalopathy—primarily John Cunningham (JC) virus–associated progressive multifocal leukoencephalopathy (PML)—has been reported in association with monoclonal antibody treatment. 7 Daratumumab is a human monoclonal antibody that targets CD38, a cell surface glycoprotein that is highly expressed on myeloma cells. Daratumumab induces cell death through various mechanisms, including direct cytotoxicity, indirect death via complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and antibody-dependent cytotoxicity. 8 To our knowledge, PML cases compose the only prior reports of daratumumab-associated leukoencephalopathy. 9,10 Here, we describe 2 patients who developed leukoencephalopathy, without evidence of PML or CNS involvement, while receiving daratumumab-based therapy for relapsed and refractory MM. A 65-year-old right-handed woman was diagnosed with IgG κ MM in 2002. Her treatment began in 2012, and she received multiple lines of therapy, including lenalidomide, bortezomib, and dexamethasone (RVd) followed by high-dose melphalan and peripheral blood autologous stem cell transplant (HDM-ASCT). She had mild peripheral neuropathy from chemotherapy, and because of progressive disease, she began receiving lenalidomide and dexamethasone (Rd) by late 2014. She developed a pulmonary embolism in 2016 and was prescribed warfarin therapy, which was eventually switched to aspirin. She continued to receive lenalidomide and dexamethasone until 2019. In March 2019, after biochemical disease progression, ixazomib was added to her chemotherapy regimen. She remained neurologically intact but developed int -Abstract Truncated-
oncology,biotechnology & applied microbiology